Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication Utrecht, The Netherlands, January 16, 2024 – AM-Pharma B.V. today announced that the first patients have been treated in a […]
• Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers and a positive safety profile in adult patients with hypophosphatasia; • Data to be presented by Lothar Seefried, MD, at the American Society for Bone and Mineral Research’s Symposium on Rare Bone Diseases on Thursday, October 12, 2023 Utrecht, The Netherlands, October 11, 2023 […]
Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage; Phase 1b study of ilofotase alfa as enzyme replacement therapy in hypophosphatasia patients being finalized, results to be announced before end of 2023; Juliane Bernholz, AM-Pharma’s Chief Operating Officer since 2019, succeeds Erik van den Berg as Chief Executive Officer. […]
Principal investigator Professor Peter Pickkers to present data at ISICEM on March 21st in Brussels and at the AKI & CRRT conference on March 29th in San Diego A significant reduction in major adverse kidney events by day 90 and no difference in 28-day all-cause mortality was observed after review of the data from all […]
Phase 3 REVIVAL study stopped per recommendation of data monitoring committee after per-protocol pre-specified interim futility analysis on the study’s primary endpoint, 28-day mortality, without any safety concern. A significant reduction in Major Adverse Kidney Events by day 90 and no difference in overall mortality was observed after review of the data for all 649 […]
Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule Utrecht, The Netherlands, 05 July 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating […]
Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET. About AM-Pharma AM-Pharma’s purpose […]
Decision from the first pre-specified futility analysis at 400 patients is expected in July Utrecht, The Netherlands, April 25, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. […]
– Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study – Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America Utrecht, The Netherlands, 12 November 2020 – AM-Pharma B.V., an emerging leader focused on the […]
JAMA paper to be presented at ESICM conference in Paris New data on mode of action to be presented at ASN conference in San Diego Bunnik, The Netherlands, 24th October 2018. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today publishes data in the prestigious Journal of the […]
